March 2021, Drugs Monitor

(28 Feb 2021) Infliximab- 37 % mortality rate in Infliximab group compared to 62 % in control group

March 1, 2021

Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit https://doi.org/10.34172/aim.2021.22 There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of… Continue reading "(28 Feb 2021) Infliximab- 37 % mortality rate in Infliximab group compared to 62 % in control group"

(28 Feb 2021) Tocilizumab- No detrimental effects for the mother and newborn

March 1, 2021

Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study https://doi.org/10.1111/jcpt.13394 A total of 12 pregnant women were identified to have received tocilizumab during pregnancy in the two hospitals. Median gestational age at admission was 27.7 weeks… Continue reading "(28 Feb 2021) Tocilizumab- No detrimental effects for the mother and newborn"

(27 Feb 2021) Dexamethasone & Methylprednisolone- mortality was 42% lower in the methylprednisolone group

March 1, 2021

A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19 https://doi.org/10.1177/0885066621994057 A total of 262 patients were grouped as receiving usual care (n = 75), methylprednisolone dosed at least at 1mg/kg/day for >/= 3 days (n = 104),… Continue reading "(27 Feb 2021) Dexamethasone & Methylprednisolone- mortality was 42% lower in the methylprednisolone group"

(26 Feb 2021) Tocilizumab- did not result in significantly better clinical status or lower mortality at 28 days

March 1, 2021

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia https://doi.org/10.1056/NEJMoa2028700 NCT04320615 (COVACTA)- Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median… Continue reading "(26 Feb 2021) Tocilizumab- did not result in significantly better clinical status or lower mortality at 28 days"

(26 Feb 2021) Antivirals- dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment

March 1, 2021

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections https://doi.org/10.1155/2021/6685921 754 subjects participated in this study: 694 patients (92.4%) who… Continue reading "(26 Feb 2021) Antivirals- dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment"

(25 Feb 2021) ACEI/ARB- showed a beneficial effect on mortality

March 1, 2021

Effect of in-hospital treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on mortality and complications in patients hospitalized for COVID-19: a large Spanish cohort study https://www.medrxiv.org/content/10.1101/2021.02.24.21252391v1 Between February and June 2020, 11,205 patients were included, with mean age… Continue reading "(25 Feb 2021) ACEI/ARB- showed a beneficial effect on mortality"

(25 Feb 2021) Lopinavir/r & Arbidol- did not significantly accelerate main symptom improvement

March 1, 2021

Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study https://doi.org/10.5414/CP203861 73 patients were divided into two groups: group LR (34 cases) and group LR+Ar (39 cases), according to the antiviral… Continue reading "(25 Feb 2021) Lopinavir/r & Arbidol- did not significantly accelerate main symptom improvement"

(24 Feb 2021) Hydroxychloroquine & Azithromycin- ineffective in hospitalized patients with mild to moderate COVID-19

March 1, 2021

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 https://doi.org/10.1016/j.bjid.2021.101549 The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was… Continue reading "(24 Feb 2021) Hydroxychloroquine & Azithromycin- ineffective in hospitalized patients with mild to moderate COVID-19"

(23 Feb 2021) Tocilizumab & methylprednisolone- showed significant impact on survival

March 1, 2021

Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients https://doi.org/10.1016/j.jtauto.2021.100086 From March 3 rd to May 7 th, 685 patients were included for analysis (58.4% males, mean age 68.9 years). Patients… Continue reading "(23 Feb 2021) Tocilizumab & methylprednisolone- showed significant impact on survival"

(23 Feb 2021) Ivermectin & Hydroxychloroquine- neither of them decreases the number of in-hospital days

March 1, 2021

Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial https://www.medrxiv.org/content/10.1101/2021.02.18.21252037v1 NCT04391127–During the month of August, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure, so we ended the recruitment… Continue reading "(23 Feb 2021) Ivermectin & Hydroxychloroquine- neither of them decreases the number of in-hospital days"

Month: March 2021